 Patent Application Title |
Patent App Num. |
Date |
| Biomimetic multiple strand fiber mesh and sutures | 20130103079 | 20130425 |
 A material comprising two or more fibers, wherein each of the fibers has a mechanical modulus, and the mechanical modulus of at least one fiber is higher than the mechanical modulus of another fiber. The higher modulus fiber has a longer length than the lower modulus fiber. In various embodiments, the higher modulus fiber is collagen mimetic and the lower modulus fiber is elastin mimetic. A suture is also described, comprising two or more fibers. At least one of the fibers is elastin-like and has a lower elastic modulus than another fiber that is collagen-like and has a higher elastic modulus. The higher modulus collagen-like fiber is longer than the lower modulus elastin-like fiber.
... |
| Collagen and elastin stimulating compositions and uses thereof | 20130052288 | 20130228 |
 Methods and compositions for preventing, ameliorating, or reducing dermatological signs of aging are provided which employ a botanical extract of Justicia ventricosa, Archidendron clypearia, Abrus fruticulosus, or combinations thereof and a cosmetically acceptable vehicle.
... |
| Chemically modified water-soluble elastin, mixed gel of chemically modified water-soluble elastin and collagen, and process for producing same | 20130040891 | 20130214 |
 A chemically modified water-soluble elastin/collagen mixed gel obtained by mixing a collagen with a chemically modified water-soluble elastin that is obtained by subjecting to N-acylating some or all of the primary amines and secondary amines contained in the molecule of a high molecular weight water-soluble elastin and coupling some or all of the carboxyl groups contained in the molecule with the amino group of an amino acid alkyl ester.
... |
| Method of culturing vascular smooth muscle cells, culture device and medical material obtained by the culture | 20130029420 | 20130131 |
 There is provided a method for culturing vascular smooth muscle cells while maintaining their normal function, and a culture device and regenerative medical material for the same. The method takes advantage of vascular smooth muscle cell recognition of elastin as an extracellular matrix. The invention provides a method for culturing vascular smooth muscle cells on elastin, a culture device having elastin anchored on the cell-growing surface, a culture device wherein the cell-growing surface is composed of an elastin molded article, and medical materials obtained by culturing vascular smooth muscle cells using such culture devices.
... |
| N-alkoxyamide conjugates as imaging agents | 20120328514 | 20121227 |
 The present disclosure is directed to compounds, diagnostic agents, and related methods. In some cases, methods for treating patients are provided. More specifically, the disclosure provides compounds, diagnostic agents, and kits for detecting and/or imaging and/or monitoring elastin rich tissues. In addition, the disclosure provides methods of detecting and/or imaging and/or monitoring the presence of coronary plaque, carotid plaque, iliac/femoral plaque, aortic plaque, renal artery plaque, plaque of any arterial vessel, aneurism, vasculitis, other diseases of the arterial wall, and/or damage or structural changes in ligaments, uterus, lungs or skin, as indicated by changes in total vessel wall area, internal lumen size, and exterior arterial perimeter.
... |
Subscribe to updates on this page: Elastin RSS  |
| Topical cosmetic preparation containing elastogenesis inducing substances associated with a systemic absorption retardant | 20120308620 | 20121206 |
| A dermatological topical formulation such as a cream, ointment, or lotion containing an elastogenesis inducer and a systemic absorption retardant is described. Such a formulation achieves high local tissue concentration of the elastogenesis inducer in the vicinity of the application site, minimizes systemic absorption of the elastogenesis inducer, and maximizes a concentration of the elastogenesis inducer in dermis, resulting in formation or restoration of elastin fibers in adult skin. The formulation can further contain a skin penetration enhancer compound.
... |
| Coating comprising an elastin-based copolymer | 20120263759 | 20121018 |
| A copolymer comprising a block of an elastin pentapeptide and method of making and using the copolymer are provided. The copolymer may be used as a coating on a stent. Methods of using a stent coated with the copolymer are also provided.
... |
| Compositions and methods for soft tissue augmentation | 20120230950 | 20120913 |
| The present invention provides compositions comprising isolated human collagen, isolated human elastin and a pharmaceutically acceptable carrier wherein the human elastin is substantially insoluble in water with a molecular weight greater than 100 kDa. The present invention further provides methods and kits for soft tissue augmentation.
... |
| Aldosterone induced elastin production | 20120195914 | 20120802 |
| Compositions and methods for inducing the deposition of elastin in skin by administering compositions including a mineralocorticoid, such as, for example, aldosterone and, optionally, a secondary active agent for enhancing or modulating the effect of the mineralocorticoid are described herein.
... |
| Method of treating skin with microrna modulators | 20120165373 | 20120628 |
| Methods for preventing, ameliorating, or reducing dermatological signs of aging are provided which employ active agents that suppress or down-regulate microRNA expression in dermal fibroblast, resulting in enhanced production of collagen, elastin and/or fibrillin in the skin. Also provided are methods for screening for activity against specific microRNAs and the methods of using active agents identified by the screening protocol in the treatment of skin.
... |
| Treatment of peyronies disease | 20120156178 | 20120621 |
| The invention relates to systems and therapeutic methods to reduce plaque causing Peyronie's disease. One approach uses high pressure injection of collagenase-containing composition into a penile plaque. Plaque disruption is enhanced by the mechanical force of the high pressure, followed by the enzymatic action of collagenase. Another approach uses collagenase as a pretreatment, followed by addition of adipose-derived stem cells ADSCs. The initial collagenase injection breaks down collagen (often more type III than type I in Peyronie's) to provide short term benefit. The longer-term benefit is provided by introduction of ADSCs to the plaque, which can produce cytokines and other signals for revascularization and restoration of normal penile tissue. The resulting combination advantageously reduces the bulk of the plaque early on with ongoing reduction through the... |
| Method and apparatus for vascular tissue sealing with reduced energy consumption | 20120123402 | 20120517 |
| An end effector assembly for use with an electrosurgical instrument is provided. The end effector assembly includes a pair of opposing jaw members configured to grasp tissue therebetween. Each of the opposing jaw members includes a non conducting tissue contact surface and an energy delivering element configured to perforate the tissue to create an opening, extract elastin and collagen from the tissue and denaturize the elastin and the collagen in the vicinity of the opening.
... |
| Elastin stabilization of connective tissue | 20120114732 | 20120510 |
| A method and product are provided for the treatment of connective tissue weakened due to destruction of tissue architecture, and in particular due to elastin degradation. The treatment agents employ certain unique properties of phenolic compounds to develop a protocol for reducing elastin degradation, such as that occurring during aneurysm formation in vasculature. According to the invention, elastin can be stabilized in vivo and destruction of connective tissue, such as that leading to life-threatening aneurysms in vasculature, can be tempered or halted all together. The treatment agents can be delivered or administered acutely or chronically according to various delivery methods, including sustained release methods incorporating perivascular or endovascular patches, use of microsphere carriers, hydrogels, or osmotic pumps.
... |
Subscribe to updates on this page: Elastin RSS |
| Hyperthermia induced deposition of elastin fibers | 20120116346 | 20120510 |
| Methods for inducing the deposition of elastin at a tissue site by exposing the tissue to hyperthermia is described herein.
... |
| Non-invasive tissue glucose-level monitoring | 20120053429 | 20120301 |
| A non-invasive analyte monitoring instrument has a radiation source for directing excitation radiation to a portion of a surface of a tissue wherein said source emits radiation at a plurality of different wavelengths that excites a target in said tissue causing said target to emit radiation such that the radiation received at the surface provides an analyte level indication of the patient. A radiation detector positioned to receive radiation emitted from the surface wherein said radiation detector is configured to synchronously scan radiation emitted by the target with the excitation radiation. A processing circuit operatively connected to the radiation detector that translates radiation received at the surface to a measurable signal to obtain said analyte level indication, wherein said radiation source comprises a visible light source... |
| Coating comprising an elastin-based copolymer | 20120046640 | 20120223 |
| The present invention is directed to medical devices including coatings. The coatings include a topcoat which includes a copolymer comprising a block of an elastin pentapeptide. The topcoat is over a layer of poly(vinyl alcohol) on a hydrophobic coating or over a porous coating comprising pores or depots that include a bioactive agent.
... |
| Crosslinked material comprising elastin and collagen, and use thereof | 20120021063 | 20120126 |
| To provide a collagen/elastin crosslinked material capable of satisfactorily corresponding to various uses such as medical materials including an artificial dermis and scaffolding materials for cell culture. The collagen/elastin crosslinked material is obtained by crosslinking a fish-derived collagen and a fish-derived elastin, and is fully capable of corresponding to various uses such as medical materials including an artificial dermis and scaffold material for cell culture.
... |
| Composite containing collagen and elastin as a dermal expander and tissue filler | 20120010146 | 20120112 |
| An injectable composition having dermal filling and tissue expanding activity comprises (1) a quantity of elastin sufficient to bring about dermal filling and tissue expansion when injected into a subject in need of dermal filling and tissue expansion, and (2) a pharmaceutically acceptable carrier. The composition can further comprise collagen, in other alternatives, the composition can further comprise hyaluronic acid, and one or more of the elastin, the collagen, and the hyaluronic acid, if present can be cross-linked, either intramolecularly or intermolecularly. The elastin, however, is the primary filler, even if collagen or hyaluronic acid are included in the composition
... |
| Combination of azelastine and steroids | 20100331289 | 20101230 |
| A pharmaceutical product or formulation, which comprises azelastine or a pharmaceutically acceptable salt, solvate or physiologically functional derivative thereof, and a steroid, or a pharmaceutical acceptable salt, solvate or physiologically functional derivative thereof, preferably the product or formulation being in a form suitable for nasal or ocular administration.
... |
| Biochemical markers for cvd risk assessment | 20100323377 | 20101223 |
| A method of bioassay for the quantification of peptide fragments comprising a neo-epitope formed by cleavage of a protein of an atherosclerotic plaque such as lumican, versican, perlecan, decorin, biglycan, collagen type III, CRP, ApoE, or elastin, by a proteinase, said comprises contacting a sample such as urine or serum with an antibody reactive with the neo-epitope and determining the level of binding of said immunological binding partner to peptide fragments in said sample. The assay is predictive of risk of cardiovascular disease events.
... |
| Novel triterpenes for modulating gene expression and cell membrane, and as antiprotozoal agents | 20100317606 | 20101216 |
| This invention provides methods, processes, compounds and compositions for modulating the gene expression or secretion of adhesion proteins, angiopoietins or their receptors to cure diseases, for anti-angiogenesis and for treating parasites, wherein the adhesion proteins or receptors comprise fibronectin, integrins family, myosin, vitronectin, collagen, laminin, glycosylation cell surface proteins, polyglycans, cadherin, heparin, tenascin, CD 54, CAM, elastin and FAK; wherein the angiopoietins comprise angiopoietin 1, angiopoietin 2, angiopoietin 3, angiopoietin 4, angiopoietin 5, angiopoietin 6, angiopoietin 7, angiopoietin-like 1, angiopoietin-like 2, angiopoietin-like 3, angiopoietin-like 4, angiopoietin-like 5, angiopoietin-like 6, and angiopoietin-like 7; wherein the cancers comprise breast cancer, leukocyte cancer, liver cancer, ovarian cancer, bladder cancer, prostate cancer, skin cancer, bone cancer, brain cancer, leukemia cancer, lung cancer, colon cancer, CNS cancer, melanoma cancer, renal cancer,... |
| Granzyme a and granzyme b diagnostics | 20100317038 | 20101216 |
| A method for identifying a subject being at risk for or having a chronic inflammatory disease, fibrillinopathy, atherosclerosis, or coronary artery disease is provided. The method may include determining the concentration of GrA and/or GrB in a blood or serum sample from said subject; and comparing the concentrations to the corresponding concentration in a control sample, wherein an elevated concentration of GrA and/or GrB may be indicative of a chronic inflammatory disease, fibrillinopathy, atherosclerosis, or coronary artery disease. The method may further include identifying concentrations of fibrinogen, elastin and/or fibrillin.
... |
| Soft tissue processing | 20100304487 | 20101202 |
| (5) dipping the tissue in 70% ethanol and packaging the tissue.
... |
| Topical compositions containing desthiobiotin and its derivatives and a method of treating skin | 20100267792 | 20101021 |
| Topical compositions and methods of use to treat symptoms of reduced skin elasticity are provided comprising desthiobiotin and certain desthiobiotin analogues. These compounds are effective in stimulating LOXL-1 activity and can thus increase elastin remodeling and improve appearance of fine lines, wrinkles, skin sagging and other symptoms of reduced elastin function.
... |
| Tissue adhesive using engineered proteins | 20100261652 | 20101014 |
| There is provided in one embodiment of the disclosure a tissue adhesive composition comprising an engineered protein having repeated blocks of an elastin domain and at least one cell-binding domain and further comprising a polymer crosslinker. When the engineered protein and the polymer crosslinker are introduced onto a tissue, the engineered protein and the polymer crosslinker initiate an in situ crosslinking reaction to form an adhesive bond that is mechanically strong, transparent, biocompatible, and stimulates regrowth of one or more tissue layers over the adhesive bond. In another embodiment of the disclosure there is provided a molded corneal onlay and method of making the same.
... |
| Methods and compositions for treating dermatological diseases and conditions | 20100249244 | 20100930 |
| The presently claimed and disclosed inventive concept(s) contemplates compositions comprising compounds, in particular dihydroeugenol (DHE) and/or isoeugenol (IE) and/or ethyl vanillin (EV) or salts, esters, ethers, or derivatives thereof, and methods for topically or systemically delivering them for treatment against inflammation-related and other dermatological conditions such as described herein. These DHE and/or IE and/or EV or salts, esters, ethers or derivatives thereof also are delivered to a measurable extent transepidermally or transdermally. In one of its method aspects, this presently claimed and disclosed inventive concept(s) is directed to a method for treating a patient with a dermatological disease or condition by topically administering to said patient a pharmaceutical or cosmetic composition comprising a pharmaceutically or cosmetically acceptable topical carrier and an effective dermatological disease, disorder or... |
| Compositions for elastogenesis and connective tissue treatment | 20100247454 | 20100930 |
| The present invention describes therapeutic compositions comprising one or more minerals, including trivalent iron, divalent manganese and salts thereof, suitable in facilitating synthesis and deposition of connective tissue matrix, particularly rich of elastin and collagen, and mitogenic potential in human dermal fibroblasts. It also describes the phenomenon in which stimulation of elastogenesis by arterial SMC associates with a net decrease in proliferation of these cell types. The present invention also describes methods of treatment of human skin fibroblasts and arterial smooth muscle cells. The therapeutic compositions of the present invention comprise one or more of trivalent iron or divalent manganese or salts thereof and may be combined with an elastic tissue digest.
... |
| Method for controlled electrospinning | 20100222771 | 20100902 |
| An electrospinning apparatus and methodology is described that produces medical devices, such as scaffolds that induce the formation of a natural fibrous structure (primarily collagen and elastin) in a tissue-engineered medical device. The apparatus uses collection surfaces designed to manipulate or change the electrostatic field so that the electrospun fibers are arranged in desirable patterns that are similar to or mimic the fibrillar structure of an animal tissue. The manipulation results in fibers that are preferentially oriented in a predefined pattern. In addition, the interfiber space between the fibers and the fiber diameter are consistently within a predefined range. Using these techniques in conjunction with controlling polymer properties enables the production of a scaffold that has the structural and mechanical characteristics similar to the native tissue.
... |
| Compositions and methods for treating signs of skin aging | 20100215785 | 20100826 |
| The invention relates to methods and compositions for treating skin aging, said compositions comprising at least one tropoelastin promoter and at least one tropoelastin crosslinker.
... |
| Fibrosis biomarker assay | 20100209940 | 20100819 |
| contacting protein fragments naturally present in said sample with an immunological binding partner reactive with a neo-epitope formed by cleavage of a protein by a proteinase and measuring the extent of binding of peptide fragments to said immunological binding partner to measure therein protein fragments comprising said neo-epitope, and wherein said protein is collagen type III, collagen type I, collagen type IV, collagen type V, or collagen type VI, elastin, biglycan, decorin, lumican, versican, perlecan, neurocan, brevican, fibromodulin, serglycin, syndecan, betaglycan, vimentin, or C-reactive protein.
... |
| Peptide fingerprint from the degradation of elastin by hne | 20100203565 | 20100812 |
| Methods for producing and using protein/peptide fingerprints, derived from elastin degraded by the enzyme human Neutrophil Elastase (HNE), allowing identification and investigation of disease-associated proteins/peptides that can be linked to specific drug targets, or to specific drug target combinations. The methods are particularly useful for studies relating to Chronic Obstructive Pulmonary Disease (COPD).
... |
| Methods for the treatment and prevention of diseases of biological conduits | 20100203034 | 20100812 |
| Methods are described for dilating biological conduits by removing elastin and remodeling collagens in the wall of the conduit. Methods include the use of agents that increase the release of endogenous elastase and collagenase in the wall of the conduit, either by cells that are normally present in the wall of the conduit or by inflammatory cells that are attracted to the conduit, thereby providing additional conduit dilation. Methods also include the use of agents that increase conduit wall permeability and expose elastin and collagen fibers. Methods also include removing components of the extracellular matrix of arteries and veins leading to an inhibition of intimal hyperplasia in the wall of the vessels by decreasing biomechanical stimuli directed toward the cells in the wall of the vessel.... |
| Compositions and methods for altering elastogenesis | 20100197563 | 20100805 |
| Compositions and methods are provided for promoting elastin fiber formation (elastogenesis) in a cell, including methods that comprise contacting a cell that is capable of elastogenesis with (i) a mutated biglycan polypeptide that lacks chondroitin sulphate proteoglycan chains, (ii) a versican V3 isoform polypeptide that lacks most or all of the polypeptide regions encoded by one or more of exons 4, 5 or 6 or by exons 9-10 or 11-13, and/or with (iii) metastatin.
... |
| Methods of validating candidate compounds for use in treating copd and other diseases | 20100196885 | 20100805 |
| The present invention relates to methods of diagnosing and treating elastin fiber injuries. In additional preferred embodiments, the present invention relates to methods of validating candidate compounds for use in treating chronic obstructive pulmonary disease (COPD), chronic bronchitis, emphysema, refractory asthma, and other related diseases. Examples of such methods include determining if the candidate compound decreases the degradation of elastic fiber in a patient administered the candidate compound by measuring, using mass spectrometry, a marker of elastic fiber degradation in a sample of a body fluid or a tissue of the patient. The invention provides that a decrease in the presence of the marker compared to a control validates that the candidate compound is effective to treat, prevent, or ameliorate the disease.
... |
| Drug delivery with stimulus responsive biopolymers | 20100189643 | 20100729 |
| The present invention provides conjugate compounds comprising (a) an active compound; (b) optionally, but in some embodiments preferably, an affinity binding agent; and (c) a block copolymer, the block copolymer comprising: (i) a first elastin-like polypeptide having a first Tt and (U) a second elastin-like polypeptide having a second Tt greater than the first Tt. Method for the targeted delivering of an active compound in vivo to a selected region within a subject with such agents are also described.
... |
| Elastin stabilization of connective tissue | 20100185272 | 20100722 |
| A method and product are provided for the treatment of connective tissue weakened due to destruction of tissue architecture, and in particular due to elastin degradation. The treatment agents employ certain unique properties of phenolic compounds to develop a protocol for reducing elastin degradation, such as that occurring during aneurysm formation in vasculature. According to the invention, elastin can be stabilized in vivo and destruction of connective tissue, such as that leading to life-threatening aneurysms in vasculature, can be tempered or halted all together. The treatment agents can be delivered or administered acutely or chronically according to various delivery methods, including sustained release methods incorporating perivascular or endovascular patches, use of microsphere carriers, hydrogels, or osmotic pumps.
... |
| Chemically and biologically modified medical devices | 20100174351 | 20100708 |
| Biocompatible materials for use in vascular applications or for implantation have been engineered, combining human recombinant tropoelastin with other synthetic or natural biomaterials to form protoelastin. The materials can be in the form of elastin films on metal or polymer substrates, laminates of alternating polymer and elastin, blends of polymer and elastin, or elastin crosslinked with or tethered to polymer or metal. These are mechanically stable, elastic, strong and biocompatible (i.e., not thrombogenic and promoting adhesion of cells, especially human endothelial cells), not eliciting a foreign body response. Plasma polymerization of substrate is shown to enhance biocompatibility, especially when used to bind elastin or other protein to the substrate.
... |
| Method for discriminating between benign and malignant prostate tumors | 20100173350 | 20100708 |
| The method for discriminating between benign and malignant prostate tumors relates to analyzing samples of blood, urine and tissue by fluorescence spectroscopy in order to detect the presence of naturally occurring molecules in the fluids and tissue that serve as biomarkers indicative of cancer in the human body. The analysis can be carried out based on fluorescence emission spectra, fluorescence excitation spectra and synchronous (emission and excitation) spectra of bio-samples. The detection, diagnosis, and follow-up and also discrimination between malignant and benign prostate tumors may be made by comparison of ratios of fluorescence emissions and/or excitation intensities of tryptophan, tyrosine, elastin, collagen, bile pigments, NADH, flavins and various species of porphyrins.
... |
| Compositions comprising azelastine and methods of use thereof | 20100152147 | 20100617 |
| The present invention provides pharmaceutical compositions comprising azelastine, or a pharmaceutically acceptable salt or ester thereof including azelastine hydrochloride, and optionally one or more additional active agents. Preferred such compositions further comprise one or more pharmaceutically acceptable carriers or excipients that reduce the amount of post-nasal drip, and/or that minimize or mask the unpleasant bitter taste associated with post-nasal drip, of the compositions into the oral cavity, upon intranasal or ocular administration of the compositions. Especially effective excipients used in the compositions of the present invention are hypromellose as a viscosity modifier and sucralose as a taste-masking agent. The invention also generally relates to pharmaceutical compositions comprising one or more active pharmaceutical ingredients, such as azelastine or pharmaceutically acceptable salts or esters thereof including azelastine hydrochloride,... |
| composition for improving skin condition and appearance | 20100143451 | 20100610 |
| Disclosed is a cosmetic composition comprising prenylated isoflavonoid and a carrier, wherein the prenylated isoflavonoid is from about 0.0000001% to about 10%, preferably from 0.00001% to 1%, most preferably from 0.01% to 1%, by weight, based on the total weight of the composition. The active agent prenylated isoflavonoid induces a statistically significant upregulation of collagen 1A1 and elastin genes in normal human dermal fibroblasts. The composition is effective to stimulate the production of collagen and elastin and improve the appearance and condition of the skin.
... |
| Cosmetic compositions for skin-tightening and method of skin-tightening using the same | 20100125048 | 20100520 |
| The present invention relates to a skin-tightening cosmetic composition and a method of applying the same, and more specifically, to a cosmetic composition a method of applying the same that includes a hydrolyzed plant protein and glycoprotein. The cosmetic composition includes a hydrolyzed plant protein and glycoprotein in an optimal amount, thereby causing the occurrence of an immediate contraction effect and a long-lasting contracting effect, and achieving skin improvements such as skin moisturizing and induction of synthesizing collagen and elastine in use of the composition over a long period of time.
... |
| Compositions for tissue stabilization | 20100119605 | 20100513 |
| Collagen crosslinking/stabilization composition optionally in combination with elastin crosslinking composition as treatment of vascular aneurysms, methods of using the compositions, especially with respect to in vivo procedures are described. The treatment is achieved through the delivery of an effective amount of crosslinking/stabilization composition to the site of the aneurysm. The crosslinking/stabilization agent may be embedded in a delivery composition and delivered to the site of aneurysm using a delivery device. The site of the aneurysm may be isolated for treatment using the delivery device. The elastin stabilization agent may be simultaneously or sequentially delivered with the collagen crosslinking/stabilization agent for the treatment of vascular aneurysms in the isolated section of blood vessel.
... |
| Elastin-like polymer delivery vehicles | 20100119529 | 20100513 |
| In invention concerns elastin-like polymer (ELP) drug delivery compositions and methods for the use thereof. In some aspects ELP delivery vehicles may be used to deliver therapeutic drugs such as Hsp90 antagonists. Furthermore, embodiments of the invention concern in vivo delivery with ELP compositions directed to target sites by the application of local hyperthermia therapy. Methods of the invention may have particular utility in the delivery of geldanamycin and related drugs.
... |
| Retinol formulations and methods for their use | 20100113352 | 20100506 |
| A composition for the treatment of skin comprises a non-emulsified, aqueous suspension of retinol. The composition may further include at least one protein species, and some proteins used in the composition include collagen and elastin. The composition may also include hyaluronic acid. The composition may also include one or more of tocopheryl acetate, propylene glycol, and linseed extract. Also disclosed are methods for making the composition and use of the composition for the treatment of skin.
... |
| Processing soft tissue, methods and compositions related thereto | 20100112543 | 20100506 |
| In certain embodiments, the present invention relates to a process for preparing skin removed from a human donor, including a living human donor, and removing cellular components and forming a decellular matrix having as major components collagens and elastins while disinfecting the tissue. In other embodiments, the present invention relates to a process for treating a decellularized soft tissue by freezing the same at a plurality of decreasing temperatures at atmosphere or higher such that there is formation of ice crystals having a size greater than 2.0 and lyophilizing the soft tissue under vacuum to remove the water to less than 6% forming a porous matrix.
... |
| Lung cancer detection by optical analysis of body fluids | 20100075367 | 20100325 |
| The method for lung cancer detection by optical analysis of body fluids relates to analyzing samples of blood, urine and sputum by fluorescence spectroscopy in order to detect the presence of naturally occurring molecules in the fluids that serve as biomarkers indicative of cancer in the human body. The analysis can be carried out based on fluorescence emission spectra, fluorescence excitation spectra and synchronous (emission and excitation) spectra of bio-samples. The early detection and diagnosis of lung cancer may be made by comparison of ratios of fluorescence emissions and/or excitation intensities of tryptophan, tyrosine, elastin, collagen, bile pigments, NADPH, flavins and various species of porphyrins.
... |
| Modified protein polymers | 20100048473 | 20100225 |
| In an embodiment, a number of synthetic protein triblock copolymers are provided comprising first and second end hydrophobic blocks separated by a central hydrophilic block. In particular, the synthetic proteins are elastin-mimetic proteins having improved mechanical characteristics and related methods of making the proteins with the capability of providing precise control over the mechanical properties. Provided are proteins used in a number of medical devices such as artificial blood vessels, shunts, stents or as embolic agents in situations where it is desired to stop or reduce blood flow or pressure in a localized region.
... |
| Composition for transplantation comprising adipose stem cells or adipocytes | 20100028310 | 20100204 |
| The present invention relates to a composition for transplantation in a physiologically compatible buffer solution comprising, (a) a transplant-cell selected among an adipose stem cell, an adipocyte, adipose tissues (fat tissue) and a mixture thereof; and (b) a semi-solid substance derived from a living body or a biodegradable substance selected among a hyaluronic acid, collagen, elastin, thrombin, chondroitin sulfate, albumin and a mixture thereof.
... |
| Combination of azelastine and steroids | 20090318397 | 20091224 |
| A pharmaceutical product or formulation, which comprises azelastine or a pharmaceutically acceptable salt, solvate or physiologically functional derivative thereof, and a steroid, or a pharmaceutical acceptable salt, solvate or physiologically functional derivative thereof, preferably the product or formulation being in a form suitable for nasal or ocular administration.
... |
| Leavened products made from non-wheat cereal proteins | 20090304861 | 20091210 |
| Gluten-free baked products, particularly gluten-free bread products, which exhibit properties comparable those made with wheat flour. Compositions and methods for preparation of gluten-free baked products. A conditioned protein or protein composite which functions to replace gluten in gluten-free flour. The conditioned protein comprises one more non-wheat cereal storage proteins, particularly prolamins, optionally, but preferably in combination with one or more co-proteins which function to facilitate formation and stabilize formation of a protein network, e.g., β-sheet network, that facilitates retention of CO2 for leavening. More specifically, protein composites of zein and or other non-wheat prolamins with co-proteins including casein, elastin or mixtures thereof conditioned at temperatures above the glass transition temperature of the protein mixture provide improved ingredients for preparation of gluten-free breads and other baked products.... |
| Medical implant comprising a biological substrate and a diamond-like carbon coating | 20090299467 | 20091203 |
| Described is an implant for use in medical applications and methods of making and using the implant. The implant includes a hydrated substrate and a diamond-like carbon coating on the substrate. The substrate may be a biological substrate, such as collagen or elastin. The implant may be used to replace or restore the function of damaged tissue in a patient requiring such treatment.
... |
| Combination of azelastine and steroids | 20090291143 | 20091126 |
| A pharmaceutical product or formulation, which comprises azelastine or a pharmaceutically acceptable salt, solvate or physiologically functional derivative thereof, and a steroid, or a pharmaceutical acceptable salt, solvate or physiologically functional derivative thereof, preferably the product or formulation being in a form suitable for nasal or ocular administration.
... |
| Pharmaceutical formulations comprising azelastine and a corticosteroid for the treatment of inflammatory or allergic conditions | 20090286762 | 20091119 |
| The present invention also relates to therapeutic uses thereof, particularly for the treatment of inflammatory and allergic conditions, specifically rhinitis.
... |
| Oral carotenoid supplementation methods for improving the health and appearance of skin | 20090285850 | 20091119 |
| Provided herein are oral skin care supplements and nutraceutical compositions and methods of use for improving the health and appearance of skin. Also provided are nutraceutical compositions that, when orally consumed will provide nourishment and deliver essential skin health nutrition to the skin. These nutraceutical compositions include omega 3 rich oils, vitamins, lutein, marine collagen and elastin. Also provided is a unique microalgae oral delivery system targeting the health and appearance of skin.
... |
| Elastin digest compositions and methods utilizing same | 20090281044 | 20091112 |
| The present invention provides compositions for the therapeutic and/or cosmetic treatment of Elastin comprising tissues. Therapeutic and cosmetic compositions comprising an elastin digest stimulate the endogenous production of Elastin and appear to enhance the elasticity of the skin and provide an external supply of peptide precursors of Elastin that penetrate into the tissue to which it is applied. The present invention describes compositions containing an elastin digest derived from proteolytic digestion of insoluble elastin derived from mammalian ligaments with a protein digesting composition, such as proteinase K. The elastin digest is a mixture of elastin peptides wherein the elastin peptide mixture comprises peptides of the sequence GXXPG, wherein X represents one of the natural amino acids. The elastin digest of the present invention may also comprise... |
| Tropoelastin for promoting endothelial cell adhesion or migration | 20090280152 | 20091112 |
| The invention provides methods, compositions, and devices for promoting adhesion or migration of endothelial cells.
... |
| Elastin digest compositions and methods utilizing same | 20090281044 | 20091112 |
| The present invention provides compositions for the therapeutic and/or cosmetic treatment of Elastin comprising tissues. Therapeutic and cosmetic compositions comprising an elastin digest stimulate the endogenous production of Elastin and appear to enhance the elasticity of the skin and provide an external supply of peptide precursors of Elastin that penetrate into the tissue to which it is applied. The present invention describes compositions containing an elastin digest derived from proteolytic digestion of insoluble elastin derived from mammalian ligaments with a protein digesting composition, such as proteinase K. The elastin digest is a mixture of elastin peptides wherein the elastin peptide mixture comprises peptides of the sequence GXXPG, wherein X represents one of the natural amino acids. The elastin digest of the present invention may also comprise... |
| Tropoelastin for promoting endothelial cell adhesion or migration | 20090280152 | 20091112 |
| The invention provides methods, compositions, and devices for promoting adhesion or migration of endothelial cells.
... |
| Method of culturing vascular smooth muscle cells, culture device and medical material obtained by the culture | 20090274664 | 20091105 |
| There is provided a method for culturing vascular smooth muscle cells while maintaining their normal function, and a culture device and regenerative medical material for the same. The method takes advantage of vascular smooth muscle cell recognition of elastin as an extracellular matrix. The invention provides a method for culturing vascular smooth muscle cells on elastin, a culture device having elastin anchored on the cell-growing surface, a culture device wherein the cell-growing surface is composed of an elastin molded article, and medical materials obtained by culturing vascular smooth muscle cells using such culture devices.
... |
| Method of culturing vascular smooth muscle cells, culture device and medical material obtained by the culture | 20090274664 | 20091105 |
| There is provided a method for culturing vascular smooth muscle cells while maintaining their normal function, and a culture device and regenerative medical material for the same. The method takes advantage of vascular smooth muscle cell recognition of elastin as an extracellular matrix. The invention provides a method for culturing vascular smooth muscle cells on elastin, a culture device having elastin anchored on the cell-growing surface, a culture device wherein the cell-growing surface is composed of an elastin molded article, and medical materials obtained by culturing vascular smooth muscle cells using such culture devices.
... |
| N-alkoxyamide conjugates as imaging agents | 20090252676 | 20091008 |
| The present disclosure is directed to compounds, diagnostic agents, and related methods. In some cases, methods for treating patients are provided. More specifically, the disclosure provides compounds, diagnostic agents, and kits for detecting and/or imaging and/or monitoring elastin rich tissues. In addition, the disclosure provides methods of detecting and/or imaging and/or monitoring the presence of coronary plaque, carotid plaque, iliac/femoral plaque, aortic plaque, renal artery plaque, plaque of any arterial vessel, aneurism, vasculitis, other diseases of the arterial wall, and/or damage or structural changes in ligaments, uterus, lungs or skin, as indicated by changes in total vessel wall area, internal lumen size, and exterior arterial perimeter.
... |
| N-alkoxyamide conjugates as imaging agents | 20090252676 | 20091008 |
| The present disclosure is directed to compounds, diagnostic agents, and related methods. In some cases, methods for treating patients are provided. More specifically, the disclosure provides compounds, diagnostic agents, and kits for detecting and/or imaging and/or monitoring elastin rich tissues. In addition, the disclosure provides methods of detecting and/or imaging and/or monitoring the presence of coronary plaque, carotid plaque, iliac/femoral plaque, aortic plaque, renal artery plaque, plaque of any arterial vessel, aneurism, vasculitis, other diseases of the arterial wall, and/or damage or structural changes in ligaments, uterus, lungs or skin, as indicated by changes in total vessel wall area, internal lumen size, and exterior arterial perimeter.
... |
| Repeat sequence protein polymer nanoparticles optionally containing active agents and their preparation | 20090246283 | 20091001 |
| A nanocomposite of a repeat sequence protein polymer, such as a copolymer of silk and elastin, is produced by Supercritical Antisolvent Precipitation with Enhanced Mass Transfer (SAS-EM). The nanocomposite may include an active agent, such as a protein or hormone, that is releasably bound to the repeat sequence protein polymer.
... |
| Treatment of aneurysm with application of connective tissue stabilization agent in combination with a delivery vehicle | 20090214654 | 20090827 |
| Delivery vehicles for controlled release of connective tissue stabilization agent for the treatment of vascular aneurysms are described. The delivery vehicle generally is combined with a connective tissue stabilization agent to form a therapeutic composition. The treatment of an aneurysm can be achieved through release of connective tissue stabilization agent from the delivery vehicle to the aneurysm. The connective tissue stabilization agent can be collagen stabilization agent, elastin stabilization agent, or a combination thereof. The aneurysm can be treated individually, simultaneously or sequentially with collagen stabilization agent and elastin stabilization agent embedded in separate delivery vehicles.
... |
| Treatment of aneurysm with application of connective tissue stabilization agent in combination with a delivery vehicle | 20090214654 | 20090827 |
| Delivery vehicles for controlled release of connective tissue stabilization agent for the treatment of vascular aneurysms are described. The delivery vehicle generally is combined with a connective tissue stabilization agent to form a therapeutic composition. The treatment of an aneurysm can be achieved through release of connective tissue stabilization agent from the delivery vehicle to the aneurysm. The connective tissue stabilization agent can be collagen stabilization agent, elastin stabilization agent, or a combination thereof. The aneurysm can be treated individually, simultaneously or sequentially with collagen stabilization agent and elastin stabilization agent embedded in separate delivery vehicles.
... |
| Treatment of aneurysm with application of connective tissue stabilization agent in combination with a delivery vehicle | 20090214654 | 20090827 |
| Delivery vehicles for controlled release of connective tissue stabilization agent for the treatment of vascular aneurysms are described. The delivery vehicle generally is combined with a connective tissue stabilization agent to form a therapeutic composition. The treatment of an aneurysm can be achieved through release of connective tissue stabilization agent from the delivery vehicle to the aneurysm. The connective tissue stabilization agent can be collagen stabilization agent, elastin stabilization agent, or a combination thereof. The aneurysm can be treated individually, simultaneously or sequentially with collagen stabilization agent and elastin stabilization agent embedded in separate delivery vehicles.
... |
| Treatment of aneurysm with application of connective tissue stabilization agent in combination with a delivery vehicle | 20090214654 | 20090827 |
| Delivery vehicles for controlled release of connective tissue stabilization agent for the treatment of vascular aneurysms are described. The delivery vehicle generally is combined with a connective tissue stabilization agent to form a therapeutic composition. The treatment of an aneurysm can be achieved through release of connective tissue stabilization agent from the delivery vehicle to the aneurysm. The connective tissue stabilization agent can be collagen stabilization agent, elastin stabilization agent, or a combination thereof. The aneurysm can be treated individually, simultaneously or sequentially with collagen stabilization agent and elastin stabilization agent embedded in separate delivery vehicles.
... |
| Treatment of aneurysm with application of connective tissue stabilization agent in combination with a delivery vehicle | 20090214654 | 20090827 |
| Delivery vehicles for controlled release of connective tissue stabilization agent for the treatment of vascular aneurysms are described. The delivery vehicle generally is combined with a connective tissue stabilization agent to form a therapeutic composition. The treatment of an aneurysm can be achieved through release of connective tissue stabilization agent from the delivery vehicle to the aneurysm. The connective tissue stabilization agent can be collagen stabilization agent, elastin stabilization agent, or a combination thereof. The aneurysm can be treated individually, simultaneously or sequentially with collagen stabilization agent and elastin stabilization agent embedded in separate delivery vehicles.
... |
| Diagnostic biomarkers for vascular aneurysm | 20090186370 | 20090723 |
| Biomarkers for diagnosis and monitoring of vascular aneurysms are described in the context of the use of assays to measure a plurality of these biomarkers. Tissue degeneration, particularly elastin and/or collagen degradation, can be monitored within patient blood (serum) and/or urine to diagnose the presence, the progression, or the likelihood of rupture of aneurismal disease. Additionally, enzymes responsible for this degradation and other biomarkers responsible for the activation or inhibition of these enzymes can be monitored additionally or alternatively. Prompt diagnosis can provide the opportunity for intervention and potentially increase the health of patients by tempering the development of debilitating and life-threatening vascular aneurysms.
... |
| Method of using and producing tropoelastin and tropoelastin biomaterials | 20090169593 | 20090702 |
| A device implantable within a human body, and a method for producing the device, are provided. The device comprises a biocompatible coating on at least a portion of an outer surface of a substrate. The biocompatible coating comprises tropoelastin. A biocompatible coating is formed in situ on the outer surface of the substrate.
... |
| Biocompatible coatings for medical devices | 20090169714 | 20090702 |
| Biocompatible coatings for implantable medical devices are disclosed. Embodiments of the invention provide methods for coating an object with a biocompatible coating wherein the device is suspended using a flowing gas during the coating process. Embodiments of the invention provide tropoelastin coatings and methods of creating tropoelastin coatings for implantable medical devices. Optionally, the biocompatible coating can be a drug eluting coating.
... |
| Method for preventing skin-cellular aging by using green algae extract and cosmetic composition containing green algae extract | 20090142370 | 20090604 |
| A method for preventing skin-cellular aging by using a green algae extract and a cosmetic composition containing the green algae extract are disclosed. An effective dose of the green algae extract is used to inhibit the activity of Metalloproteinase (MMP) in the fibroblast and to promote of collagens and elastins production in the fibroblast. The green algae extract can be mixed with a skin permeable cosmetic composition so that the cosmetic composition performs the effect of preventing extrinsic skin aging.
... |
| Methods and compositions for increasing skin remodeling | 20090137458 | 20090528 |
| Skin remodeling is stimulated at the site of blemished skin using an ionic metal-peptide complex to diminish or remove the skin imperfection. The blemish can be a scar, especially surgical or wound scars, acne scars, keloid scars, and the like, or a skin tag, callus, benign skin mole, stretch marks, facial keratosis, thickened sunspots of the skin, or a vitiligo spot. The peptide-ionic metal complex is comprised of an ionic metal selected from copper(II), tin(II), tin(IV), and zinc(II), and salts thereof, and the peptide component can be a hydrolysis of casein, collagen, elastin, meat products, silk protein, or soybean protein, or a chemically synthesized dipeptide, tripeptide, tetrapeptide or the like which complexes with the ionic metal.
... |
| Biocompatible coatings for medical devices | 20090130293 | 20090521 |
| Biocompatible coatings for implantable medical devices are disclosed. Embodiments of the invention provide plasma etch processes, surface silanization processes, and protein coating processes. Embodiments of the invention provide tropoelastin coatings and methods of creating tropoelastin coatings for implantable medical devices. Optionally, the biocompatible coating can be a drug eluting coating.
... |
| Elastin protective polyphenolics and methods of using the same | 20090110709 | 20090430 |
| Dermal fibroblasts permanently loose their ability to synthesize elastin, the major component of elastic fibers, shortly after puberty. This progressive loss of elastic fibers cannot be replaced, resulting in the physical signs of aging. The present invention provides methods and compositions containing the polyphenols ellagic acid and/or tannic acid for protection against degradation of cutaneous elastic fibers by the elastolytic enzymes. The use of ellagic acid and/or tannic acid increased the overall deposition of elastic fibers in healthy and damaged skin cells. The protection of both intra-tropoelastin and extra-cellular mature elastic fibers from proteolytic enzymes by ellagic acid and tannic acid caused an increase in the net deposition of elastic fibers. Therefore, embodiments of the present invention provide methods and composition for the treatment of skin... |
| Skin-revitalizing cosmetic composition | 20090098214 | 20090416 |
| The invention provides a skin-revitalizing cosmetic composition for alleviating or eliminating skin problems such as dry skin, wrinkles, and age spots, the composition containing a skin-revitalizing agent at high concentration. The skin-revitalizing cosmetic composition contains a skin-revitalizing agent selected from the group consisting of aloe extract, placenta extract, hydrolyzed elastin, hydrolyzed collagen, and sodium hyaluronate, wherein the skin-revitalizing agent is in the form of nanoparticles obtained through a nanoparticle-forming treatment.
... |
| Plant-derived elastin binding protein ligands and methods of using the same | 20090082280 | 20090326 |
| The present invention describes novel plant derived elastin-like peptides and peptidomimetics that may serve as functional ligands for elastin receptors and stimulate elastogenesis. The novel plant derived peptides provide an alternative (non-animal derived) source of GXXPG (SEQ ID NO. 2) containing peptides. The present invention also describes therapeutic compositions containing novel plant derived peptides or peptidomimetics useful in stimulating elastogenesis and capillary dilatation. The therapeutic compositions of the present invention that comprise novel plant derived peptides or peptidomimetics may be combined with other therapeutic agents.
... |
| Synthetic peptide materials for joint reconstruction, repair and cushioning | 20090075868 | 20090319 |
| In joint reconstruction, repair and cushioning applications, a synthetic polypeptide material is useful that contains cross-linked polypeptides that are modeled on human elastin or other fibrous proteins. The polypeptides comprise at least three consecutive beta-sheet/beta-turn structures and at least one amino acid residue that participates in cross-linking.
... |
| In-situ crosslinkable elastin-like polypeptides for defect filling in cartilaginous tissue repair | 20080312156 | 20081218 |
| Defects in a cartilaginous tissue are filled by: (a) mixing (i) a first reagent composition preferably comprising an amine-free hydroxyalkyl (preferably hydroxymethyl) phosphine crosslinking agent with (ii) a second reagent composition comprising a bioelastic polymer, the bioelastic polymer preferably comprising elastomeric units, the elastomeric units preferably selected from the group consisting of bioelastic pentapeptides, tetrapeptides, and nonapeptides; to produce a therapeutic composition; and then (b) administering the therapeutic composition to the cargilagenous tissue. Compositions and kits for carrying out the method are also described.
... |
| Apparatus for attachment and reinforcement of tissue, apparatus for reinforcement of tissue, methods of attaching and reinforcing tissue, and methods of reinforcing tissue | 20080294222 | 20081127 |
| In another embodiment, the method includes applying energy to tissue surfaces with an energy applicator, and applying a biopolymer material into the tissue surfaces with a biopolymer applicator disposed on a housing in connection with the energy applicator. Other embodiments are also disclosed.
... |
| Method and composition for restoration of age related tissue loss in the face or selected areas of the body | 20080274946 | 20081106 |
| A treatment method for restoring of age related tissue loss in the face or selected areas of the body is disclosed which includes injecting an injectable composition containing a growth factor and hyaluronic acid as a carrier into the dermis, the hypodermis, or both, in various areas of the face, or selected areas of the body of a person to stimulate collagen, elastin, or fat cell production, thereby restoring age related tissue loss in the face and selected areas of the body. Further disclosed is an injectable composition for restoring of age related tissue loss in the face and selected areas of the body, which contains a growth factor and hyaluronic acid as a carrier for providing time release of the growth factor into tissues. The... |
| Tropoelastin isoforms and used thereof | 20080269463 | 20081030 |
| This disclosure provides new isoforms of tropoelastin. The disclosure further provides methods for making and using these isoforms, alone or in combination with each other or other isomers, such as in the production of biomaterials.
... |
| Topical skin compositions, their preparation, and their use | 20080124409 | 20080529 |
| Topical skin compositions include a complex containing components to provide a defense against the various pathway mechanisms of free radicals, reactive oxygen species, reactive nitrogen species, and other oxidizing species on the human body including the skin. The compositions may be administered by topically applying them in an amount to inhibit those mechanisms. The compositions and methods are directed to the prevention of the adverse or detrimental effects of free radicals, reactive oxygen species, reactive nitrogen species, and other oxidizing species on the human body including the skin. Thus, the compositions according to the invention improve barrier function, inhibit elastase and collagenase, and/or promote synthesis of collagen and elastin.
... |
| Tropoelastin-based protoelastin biomaterials | 20080107708 | 20080508 |
| Biocompatible materials suitable for use in vascular applications have been engineered, combining human recombinant tropoelastin with other synthetic or natural biomaterials to form protoelastin. The materials can be in the form of elastin films on metal, bone, ceramic or polymer substrates, laminates of alternating polymer and elastin, blends of polymer and elastin, or elastin crosslinked with or tethered to polymer. The flexibility in engineering and design makes protoelastin biomaterials suited not only to the production of conduits but any number of other vascular applications that require blood contacting surfaces. Tropoelastin and the subsequently engineered biomaterial protoelastin provide the opportunity to satisfy a large unmet need for a biocompatible material adaptable enough to meet a range of diverse vascular uses. These are mechanically stable, elastic, strong and... |
| Multiple point detacher system | 20080109057 | 20080508 |
| Embodiments of the invention include a method for treating an aneurysm, comprising: providing a biocompatible polymeric sleeve, string or coil or combination of sleeve, string or coil, made from a material selected from one or more of a group consisting of an acrylamide, a methacrylate, cyclodextran, synthetic elastin polymer, poly chelating amphiphilic polymers, hydrogels, hyaluronic acid conjugates, polyanhydrides, glycolipids, polysaccharides, and halamines, natural hydrogel, a synthetic hydrogel, silicone, polyurethane, polysulfone, cellulose, polyethylene, polypropylene, polyamide, polyimide, polyester, polytetrafluoroethylene, polyvinyl chloride, epoxy, phenolic, neoprene, polyisoprene, and a combination thereof; transporting the sleeve, string or coil to an aneurysm; filling the aneurysm with the sleeve, coil, or string; and detaching the sleeve, string or coil
... |
| Water-soluble elastin, process for producing same, and food and medicine containing same | 20080096812 | 20080424 |
| A low-molecular-weight water-soluble elastin having a molecular weight of about 10,000 to 30,000 and a high-molecular-weight water-soluble elastin having a molecular weight of about 30,000 to 300,000 are provided, 79% to 84% of the constituent amino acids of the elastin comprising proline, glycine, alanine, and valine, 2% to 3% comprising aspartic acid and glutamic acid, 0.7% to 1.3% comprising lysine, histidine, and arginine, and 0.2% to 0.4% comprising desmosine and isodesmosine. The low-molecular-weight water-soluble elastin that is obtained may be used in a functional food or a medicine. Such a high-purity water-soluble elastin may be produced by obtaining pure insoluble elastin by subjecting animal body tissue to a collagen removal treatment and then fragmenting the insoluble elastin by means of a solubilizing liquid. It may be... |
| Topical skin compositions, their preparation, and their use | 20080081034 | 20080403 |
| Topical skin compositions include a complex containing components to provide a defense against the various pathway mechanisms of free radicals, reactive oxygen species, reactive nitrogen species, and other oxidizing species on the human body including the skin. The compositions may be administered by topically applying them in an amount to inhibit those mechanisms. The compositions and methods are directed to the prevention of the adverse or detrimental effects of free radicals, reactive oxygen species, reactive nitrogen species, and other oxidizing species on the human body including the skin. Thus, the compositions according to the invention improve barrier function, inhibit elastase and collagenase, and/or promote synthesis of collagen and elastin.
... |
| Topical skin compositions, their preparation, and their use | 20080081082 | 20080403 |
| Topical skin compositions include a complex containing components to provide a defense against the various pathway mechanisms of free radicals, reactive oxygen species, reactive nitrogen species, and other oxidizing species on the human body including the skin. The compositions may be administered by topically applying them in an amount to inhibit those mechanisms. The compositions and methods are directed to the prevention of the adverse or detrimental effects of free radicals, reactive oxygen species, reactive nitrogen species, and other oxidizing species on the human body including the skin. Thus, the compositions according to the invention improve barrier function, inhibit elastase and collagenase, and/or promote synthesis of collagen and elastin.
... |
| Protease susceptibility ii | 20080058261 | 20080306 |
| The manipulation of the amino acid sequence of tropoelastin, particularly human tropoelastin, to modify its protease susceptibility is described. The modified tropoelastins include tropoelastin derivatives having modified protease susceptibility, peptidomimetic molecules which contain amino acid sequences which correspond to or incorporate the protease susceptible sequences of tropoelastin. Uses of these tropoelastin derivatives and peptidomimetic molecules are provided. Also provided are nucleic acid molecules and genetic constructs encoding the amino acid sequences of the derivatives and peptidomimetic molecules of the invention.
... |
| Elastin producing fibroblast formulations and methods of using the same | 20080050346 | 20080228 |
| The present invention describes therapeutic compositions comprising fibroblasts that have been stimulated to increase expression of extracellular matrix components or elastin, or to produce enhanced elastogenesis or the appearance thereof at a site of administration. The therapeutic fibroblast formulations can be prepared using a variety of elastogenic agents, including digests of mammalian elastin, chemically digested plant extracts comprising elastin-like peptides, and synthetic elastogenic peptides. The invention further comprises cosmetic and pharmaceutical treatment methods using the therapeutic fibroblast compositions of the invention.
... |
| Cosmetic lightening preparation | 20080050459 | 20080228 |
| A cosmetic preparation comprises an effective amount of Phyllanthus Embilca fruit extract and at least one oligopeptide such as Oligopeptide-4 and Oligopepticje-5 (pro-Elastin oligopeptide) The cosmetic preparation may further comprise Licorice extract, and Alpha-arbutin. It has surprisingly been found that this cosmetic preparation displays a beneficial synergistic effect for the combined treatment of fine line and wrinkles and/or skin brightening.
... |
| Wound healing compositions and methods using tropoelastin and lysyl oxidase | 20080038243 | 20080214 |
| The present invention provides compositions and methods for promoting wound healing. The composition comprises virgin monomers of tropoelastin and lysyl oxidase. When the lysyl oxidase comes in contact with the tropoelastin, cross-linking of the tropoelastin monomers will occur to form elastin. Contacting the tropoelastin and lysyl oxidase together and applying the mixture to a wound before substantial cross-linking has occurred promotes wound healing by holding the damaged tissue together, increasing the rate of healing, and decreasing the amount of scarring.
... |
| Coating comprising an elastin-based copolymer | 20080038310 | 20080214 |
| A copolymer comprising a block of an elastin pentapeptide and method of making and using the copolymer are provided.
... |
| Dry powder formulations of antihistamine for nasal administration | 20080038358 | 20080214 |
| Dry powder formulations of drugs such as antihistamine for nasal administration are provided where the drug is retained in the nasal cavity, and systemic side effects minimized or eliminated, through the selection of a narrow particle size range, between approximately 10 and 20 microns in diameter. In a preferred embodiment wherein the drug is an antihistamine, retention of the antihistamine at the nasal mucosa is improved and the bitter aftertaste associated with liquid antihistamine formulations significantly reduced. By making a dry powder formulation of an antihistamine (e.g., azelastine) having an average particle size of between 10 and 20 microns, the antihistamine is restricted primarily to the desired target organ, the nasal mucosa. Because the active ingredient stays in the nasal region, a lower dose can be... |
| Tropoelastin derivatives | 20080039397 | 20080214 |
| The invention relates to derivatives of tropoelastin and variants of those derivatives. The invention further provides expression products and hybrid molecules of the derivatives and variants of the invention. The invention further provides methods for the production of the derivatives, variants, expression products and hybrid molecules. Further provided are formulations, cross-linked structures and implants comprising the derivatives, variants, expression products and hybrid molecules of the invention. Further provided are uses of the derivatives, variants, expression products and hybrid molecules of the invention.
... |
| Method for preparing biological scaffold materials | 20080027562 | 20080131 |
| A method for preparing a scaffold material for use in the prosthesis therapy is disclosed. The method comprises (a) lyophilizing a segment of native soft tissue of mammalian origin, heating the lyophilized tissue at a temperature of 100-200° C., and incubating the tissue with elastase to selectively remove elastin leaving the extracellular components mainly comprised of collagen.
... |
| Elastin-based copolymers | 20070286885 | 20071213 |
| A copolymer comprising a block of an elastin pentapeptide and method of making and using the copolymer are provided.
... |
| Elastin stabilization of connective tissue | 20070281026 | 20071206 |
| A method and product are provided for the treatment of connective tissue weakened due to destruction of tissue architecture, and in particular due to elastin degradation. The treatment agents employ certain unique properties of phenolic compounds to develop a protocol for reducing elastin degradation, such as that occurring during aneurysm formation in vasculature. According to the invention, elastin can be stabilized in vivo and destruction of connective tissue, such as that leading to life-threatening aneurysms in vasculature, can be tempered or halted all together. The treatment agents can be delivered or administered acutely or chronically according to various delivery methods, including sustained release methods incorporating perivascular or endovascular patches, use of microsphere carriers, hydrogels, or osmotic pumps.
... |
| Medical devices and methods for local delivery of elastin-stabilizing compounds | 20070282422 | 20071206 |
| This invention relates to medical devices and an elastin-stabilizing compound, such as a phenolic tannin, the medical device being adapted to release the elastin-stabilizing compound within a body of a patient. This invention also relates to medical devices and methods of treatment of disease, such as aneurysms and aortic dissection. Medical devices may include coated stents, grafts, stent grafts, balloons and catheters.
... |
| Elastin-like polymer delivery vehicles | 20070265197 | 20071115 |
| In invention concerns elastin-like polymer (ELP) delivery compositions and methods for the use thereof. In some aspects ELP compositions may be used to deliver therapeutic nucleic acids, polypeptides of small molecules. In some aspects, in vivo delivery with ELP compositions can directed to specific target sites by the application of local hyperthermia therapy. Compositions and methods for ELP gene therapy are provided.
... |
| Preventive and remedy for collagen or elastin metabolic disorder | 20070248944 | 20071025 |
| The present invention relates to a prophylactic agent or a therapeutic agent for a disorder of collagen or elastin metabolism, which comprises a a substance possessing JNK inhibitory activity as an active ingredient.
... |
| Methods and compositions for the diagnosis of diseases of the aorta | 20070224643 | 20070927 |
| The present invention relates to methods and compositions for symptom-based differential diagnosis, prognosis, and determination of treatment regimens in subjects. In particular, the invention relates to the use of biomarkers, either individually or in combinations with one another to rule in or out diseases of the aorta and its branches, most particularly aortic aneurysm and/or aortic dissection, and for risk stratification in such conditions. Preferred markers include one or more of creatine kinase-BB (CK-BB), creatine kinase-MB (CK-MB), acidic calponin, basic calponin, B-type natriuretic peptide (BNP), NT-proBNP, proBNP, BNP79-108, BNP3-108, caldesmon, caspase-3, D-dimer, soluble elastin fragments, endothelial cell-selective adhesion molecule (ESAM), fibrillin-1, heart-type fatty acid binding protein, MMP-9, myeloperoxidase, myoglobin, smooth muscle myosin, smooth muscle myosin heavy chain, TIMP-1, free cardiac troponin I, complexed cardiac troponin I,... |
| Methods, systems and compositions for skin care | 20070172431 | 20070726 |
| The present invention describes systems, methods, and compositions for treatment and maintenance of skin. The invention includes a skin care system that addresses the problems of skin aging and inflammation. The invention further includes skin care systems, methods and compositions containing active ingredients that may inhibit matrix metalloproteniases (MMPs) or that may inhibit inflammatory processes of cells, prevent moisture loss, improve skin tone (or firmness), stimulate the production of collagen and elastin, decrease the breakdown of collagen and elastin, and prevent damage to the skin caused by environmental factors.
... |
| Medical device with coating that promotes endothelial cell adherence | 20070156232 | 20070705 |
| This invention provides compositions and methods for producing a medical device coated with a matrix and an antibody which reacts with an endothelial cell antigen. The matrix coating the medical device may be composed of synthetic material, such as polyurethane, poly-L-lactic acid, cellulose ester or polyethylene glycol. In another embodiment, the matrix is composed of naturally occurring materials, such as collagen, fibrin, elastin, amorphous carbon. In a third embodiment, the matrix may be composed of fillerenes. The fullerenes range from about C60 to about C100. The medical device may be a stent or a synthetic graft. The antibodies promote adherence of eadothelial cells on the medical device. The antibodies may be mixed with the matrix or covalently tethered through a linker molecule to the matrix. Following... |
| Methods for the treatment and prevention of diseases of biological conduits | 20070141042 | 20070621 |
| Methods are described for dilating biological conduits by removing elastin and remodeling collagens in the wall of the conduit. Methods include the use of agents that increase the release of endogenous elastase and collagenase in the wall of the conduit, either by cells that are normally present in the wall of the conduit or by inflammatory cells that are attracted to the conduit, thereby providing additional conduit dilation. Methods also include the use of agents that increase conduit wall permeability and expose elastin and collagen fibers. Methods also include removing components of the extracellular matrix of arteries and veins leading to an inhibition of intimal hyperplasia in the wall of the vessels by decreasing biomechanical stimuli directed toward the cells in the wall of the vessel.... |
| Extracts of durian fruit for use in skin care compositions | 20070116789 | 20070524 |
| The present invention relates to compositions comprising extracts of Durio zibethinus. The compositions of the present invention are useful for improving the appearance, texture, and/or moisture of mammalian skin. In particular, the compositions of the present invention decrease inflammation in the skin, inhibit matrix metalloprotease-9, which degrades skin proteins such as collagen and elastin, and inhibit melanogenesis in the skin.
... |
| Environments that maintain function of primary liver cells | 20070092861 | 20070426 |
| Surfaces useful for cell culture comprise a support to which is bound a CAR material, and, bound to the CAR material, an ECM protein, or a biologically active fragment or variant thereof such as elastin, fibronectin, vitronectin, lamninin, collagen I, collagen III, collagen IV, and collagen VI. Also, optionally present on the surface is an active factor, preferably a polycationic polymer or a biologically active fragment or variant thereof, such as polyethyleneimine (PEI), poly-D-lysine (PDL), poly-L-lysine (PLL), poly-D-ornithine (PDO) or poly-L-ornithine (PLO). This surface is used in cell culture to promote cell attachment, survival, maintenance of function, and/or proliferation of primary liver cells. The invention also relates to methods utilizing this surface, such as methods for attachment, survival, maintenance of function, and/or proliferation of cells. Further... |
| Fructoseamine 3 kinase and the formation of collagen and elastin | 20070065443 | 20070322 |
| The invention relates to the discovery that levels of collagen and elastin can be modulated by changing the flux through the Amadori Pathway and that copper containing compounds and complexes inhibit the enzyme fructoseamine-3-kinase.
... |
| Extracts of durian fruit for use in skin care compositions | 20070042064 | 20070222 |
| The present invention relates to compositions comprising extracts of Durio zibethinus. The compositions of the present invention are useful for improving the appearance, texture, and/or moisture of mammalian skin. In particular, the compositions of the present invention decrease inflammation in the skin, inhibit matrix metalloprotease-9, which degrades skin proteins such as collagen and elastin, and inhibit melanogenesis in the skin.
... |
| Composition and method for neck skin firming | 20070031367 | 20070208 |
| A topical composition and method for its use for reducing sagging or wrinkles in the neck area of human skin. The composition includes safe and effective amounts of a mild topical astringent (such as Camphor) for skin tightening, a topical antispasmodic (such as benzaldehyde or benzyl cinnamate) for skin smoothing, and a topical skin irritant to increase localized skin circulation. The composition can also optionally include palmitoyl oligiopeptides to stimulate production of collagen and elastin in skin, a mushroom or plant leaf ferment extract to increase the cell turnover rate skin, and to increase hydration, skin firmness and elimination of fine facial lines, a cocao ferment extract to inhibit lipid peroxidation, inhibit excess ornithine decarboxylase activity, and stimulate cutaneous blood flow to reduce lines and wrinkles,... |
| Compositions comprising azelastine and methods of use thereof | 20070020330 | 20070125 |
| The present invention provides pharmaceutical compositions comprising azelastine, or a pharmaceutically acceptable salt or ester thereof including azelastine hydrochloride, and optionally one or more additional active agents. Preferred such compositions further comprise one or more pharmaceutically acceptable carriers or excipients that reduce the amount of post-nasal drip, and/or that minimize or mask the unpleasant bitter taste associated with post-nasal drip, of the compositions into the oral cavity, upon intranasal or ocular administration of the compositions. Especially effective excipients used in the compositions of the present invention are hypromellose as a viscosity modifier and sucralose as a taste-masking agent. The invention also provides methods of treating or preventing certain disorders, or symptomatic relief therefrom, by administering the compositions of the invention to a patient, e.g., for the... |
| Direct drug delivery system based on thermally responsive biopolymers | 20070009602 | 20070111 |
| A method for delivering a drug depot of a compound of interest to a selected region in a subject. The method comprises administering a composition directly to said region of interest, the composition comprising the compound of interest to be delivered (such as an antiinflammatory agent or a chemotherapeutic agent) and a polymer (such as an elastin-like peptide or ELP) that undergoes an inverse temperature phase transition, so that a sustained release of the compound of interest at the selected region is provided. Compositions useful for carrying out the invention are also described.
... |
| Topical skin compositions, their preparation, and their use | 20070003536 | 20070104 |
| Topical skin compositions include a complex containing components to provide a defense against the various pathway mechanisms of free radicals, reactive oxygen species, reactive nitrogen species, and other oxidizing species on the human body including the skin. The compositions may be administered by topically applying them in an amount to inhibit those mechanisms. The compositions and methods are directed to the prevention of the adverse or detrimental effects of free radicals, reactive oxygen species, reactive nitrogen species, and other oxidizing species on the human body including the skin. Thus, the compositions according to the invention improve barrier function, inhibit elastase and collagenase, and/or promote synthesis of collagen and elastin.
... |
| Tissue material and process for bioprosthesis | 20070005132 | 20070104 |
| A biomaterial useful for bioprostheses such as bioprosthetic heart valves is provided in which the fixed tissue has improved elastic properties. The high elastin-containing biomaterial is further characterized by having anisotropic properties wherein the biological material has a greater stiffness in one direction and a greater elasticity in a cross direction. For instance, the biological material has an elastin content of about 30% by weight. In one embodiment, the biological material is vena cava tissue.
... |
| Method for using tropoelastin and for producing tropoelastin biomaterials | 20070005148 | 20070104 |
| It is a general object of the invention to provide a method of effecting repair or replacement or supporting a section of a body tissue using tropoelastin, preferably crosslinked tropoelastin and specifically to provide a tropoelastin biomaterial suitable for use as a stent, for example, a vascular stent, or as conduit replacement, as an artery, vein or a ureter replacement. The tropoelastin biomaterial itself can also be used as a stent or conduit covering or coating or lining.
... |
| Elastin peptide fingerprints and analysis methods for mmp12 related to copd | 20060292631 | 20061228 |
| Methods for producing and using protein/peptide fingerprints, allowing identification and investigation of disease-associated proteins/peptides that can be linked to specific drug targets, or to specific drug target combinations. The methods are particularly useful for studies relating to Chronic Obstructive Pulmonary Disease (COPD), especially for the enzyme MMP12.
... |
| Soft tissue processing | 20060275377 | 20061207 |
| The present invention is a process for preparing soft tissue such as tendons, ligaments, cartilage, fascia, dermis, human valves and human veins for implant in a human and removes cellular components and forms an decellular matrix having as major components collagens and elastins while sterilizing the tissue. The process comprises the following steps: (1) isolating from a suitable donor a desired soft tissue sample of the biological material; (2) processing and decellularizing the soft tissue including inspection for visual defects, trimming and soaking the tissue in a detergent depending on whether the tissue is fascia or dermis and rinsing same with sterile water; (3) sterilizing the soft tissue in a vacuum and soaking the tissue in an antibiotic composition or peracetic acid depending on whether the... |
| Electrospun blends of natural and synthetic polymer fibers as tissue engineering scaffolds | 20060263417 | 20061123 |
| Non-woven fibrous scaffolds made by electrospinning from the synthetic biodegradable polymer such as, for example, poly(lactic-co-glycolic acid) (PLGA) and natural proteins, such as, for example, gelatin (denatured collagen) and elastin and a method of making thereof.
... |
| Intein-mediated protein purification using in vivo expression of an elastin-like protein | 20060263855 | 20061123 |
| Purification of recombinant proteins is performed by expressing in a host cell a fusion protein comprising: (a) a product protein domain, (b) an intein, and (c) at least one aggregator protein domain, wherein the aggregator protein domain comprises a self-aggregating protein such as elastin-like proteins (ELPs).
... |
| Elastin protective polyphenolics and methods of using the same | 20060264375 | 20061123 |
| Dermal fibroblasts permanently loose their ability to synthesize elastin, the major component of elastic fibers, shortly after puberty. This progressive loss of elastic fibers cannot be replaced, resulting in the physical signs of aging. The present invention provides methods and compositions containing the polyphenols ellagic acid and/or tannic acid for protection against degradation of cutaneous elastic fibers by the elastolytic enzymes. The use of ellagic acid and/or tannic acid increased the overall deposition of elastic fibers in healthy and damaged skin cells. The protection of both intra- tropoelastin and extra-cellular mature elastic fibers from proteolytic enzymes by ellagic acid and tannic acid caused an increase in the net deposition of elastic fibers. Therefore, embodiments of the present invention provide methods and composition for the treatment of... |
| Composite graft | 20060257447 | 20061116 |
| Composite vascular grafts, their methods of construction, and methods of use are disclosed. In some embodiments, the grafts are tubular multilayer composite grafts having a luminal blood-contacting elastin layer and an outer collagen layer to impart mechanical strength to the elastin layer. The elastin and collagen layers may comprise substantially acelluar matrixes isolated from the tissue of an animal. In particular embodiments the blood contacting layer consists essentially of pure elastin, and is substantially free of collagen. An adhesive may be used to secure the collagen and elastin layers to one another. Growth factors may be added to the adhesive of the elastin or collagen layers to promote in growth of cells into the graft.
... |
| Elastin stabilization of connective tissue | 20060240066 | 20061026 |
| A method and product are provided for the treatment of connective tissue weakened due to destruction of tissue architecture, and in particular due to elastin degradation. The treatment agents employ certain unique properties of phenolic compounds to develop a protocol for reducing elastin degradation, such as that occurring during aneurysm formation in vasculature. According to the invention, elastin can be stabilized in vivo and destruction of connective tissue, such as that leading to life-threatening aneurysms in vasculature, can be tempered or halted all together. The treatment agents can be delivered or administered acutely or chronically according to various delivery methods, including sustained release methods incorporating perivascular or endovascular patches, use of microsphere carriers, hydrogels, or osmotic pumps.
... |
| Extracting biopolymers from a biomass using ionic liquids | 20060241287 | 20061026 |
| Methods for using ionic liquids to extract and separate a biopolymer from a biomass containing the biopolymer are disclosed. Methods for dissolving a biopolymer in an ionic liquid are also disclosed. A recovery solvent is used to reduce the solubility of the biopolymer in the ionic liquid and conventional separation techniques are used to recover the biopolymer. Biopolymers encompassed by this invention include chitin, chitosan, elastin, collagen, keratin and polyhydroxyalkanoate.
... |
| Composition for promoting production of type 1 collagen and/or elastin | 20060233738 | 20061019 |
| This invention aims to provide a composition that promotes the production of type I collagen and/or elastin in the human skin fibroblast cells, wherein the composition improves the suppleness and elasticity of the skin, is amply effective in preventing and improving wrinkles and sagging, and is also very safe to the skin. The present invention relates to a composition that contains silymarin, which is a general term for flavonolignans such as silybin, silydianin, silychristin and isosilybin, wherein the aforementioned composition has a property to promote the production of type I collagen and/or property to promote the production of elastin. It also relates to a composition containing silymarin derived from a silymarin-containing plant and/or extract of such plant, wherein the aforementioned composition also has a property to... |
| Methods for assessing emphysema | 20060211026 | 20060921 |
| Emphysema and COPD are diagnosed, and the efficacy of therapeutic drug candidates for the treatment of emphysema and/or COPD is evaluated, by determining biomarkers selected from the group SpB, desmosine, VEGF, IGFBP2, MMP12, TIMP1, MMP9, Crabp2, Rbp1, Cyp26a1, Tgm2, Timp3, Adam17, Serpina1, Slpi, Col1a1, Eln, TGFβ1, TGFβ-RII, Sftpa1, Csf2, Cxcl1, Cxcl2, Cxcl5, IL-8Rβ, IL-8Rα, IL-6, TNF, EGF-R, Areg, PDGFα, HpGF, FGF7, Kdr, flt1, Angpt1, Tek, HIF1α, Hyou1, PGF, and tropoelastin.
... |
| Crosslinked elastin and process for producing the same | 20060204529 | 20060914 |
| A crosslinked elastin, a water-soluble crosslinking agent to be used for crosslinking, molded elastin articles, medical instruments and regeneration tissues using the crosslinked elastin, and a surgical therapy method and regeneration treatment wherein the medical instruments are employed. There is provided a biocompatible functional material having elasticity suitable for transplantation into the body without causing detachment of cell adhesion proteins.
... |
| Plant based formulations for improving skin moisture, texture, and appearance | 20060198810 | 20060907 |
| The present invention relates to formulations of ingredients that are useful for improving the appearance, texture and/or moisture of skin. In particular, the formulations of the present invention stimulate collagen, elastin, and lipid synthesis and/or inhibit or minimize the loss of collagen, elastin, and lipids in the skin. Additionally, the formulations of the present invention inhibit matrix metalloproteases, such as MMP-1, MMP-9, collagenase, or elastase.
... |
| Molded elastin article and process for producing the same | 20060194036 | 20060831 |
| There is provided an elastin molded article having flexibility, a biological absorption property and tear strength which is practically suturable by using a fiber structure comprising aliphatic polyester fibers having an average fiber diameter of 0.05 to 50 μm as a supporting base material. The elastin molded article is useful as a raw material for a tube or artificial blood vessel to be implanted in a body that has a biological absorption property and has tear strength and flexibility which allow the tube or artificial blood vessel to endure suture at the time of operation or the like.
... |
| Stabilized protein compositions for topical administration and methods of making same | 20060182766 | 20060817 |
| A stabilizing composition that also enhances permeation is provided for the topical or transdermal administration of an active ingredient. The composition comprises collagen, elastin, sphingoside and cerebroside. Also provided are pharmaceutical or cosmetic formulations comprising an effective amount of an active agent and the stabilizing composition as well as methods of administering active agents topically or transdermally.
... |
| Stabilized compositions for topical administration and methods of making same | 20060182794 | 20060817 |
| A stabilizing composition that also enhances permeation is provided for the topical or transdermal administration of an active ingredient. The composition preferably comprises collagen, elastin, sphingoside and cerebroside. Also provided are pharmaceutical or cosmetic formulations comprising an effective amount of an active agent and the stabilizing composition as well as methods of administering active agents topically or transdermally.
... |
| Synovial fluid barrier | 20060178743 | 20060810 |
| A composite tissue formed in situ is provided. The composite tissue includes a synovial joint tissue; and a barrier material adhered thereto for sealing the synovial joint tissue against synovial fluid. Also provided is a method for regenerating synovial joint tissue in situ by excluding synovial fluid therefrom. The method includes providing a synovial joint tissue having a defect; and placing a barrier material in intimate contact with the defect for sealing the defect against synovial fluid. The barrier material includes a curable protein copolymer. The method further includes curing the protein copolymer in situ. The barrier material can include a crosslinked network, or a self gelled network of repeating elastin-like and fibroin-like polymer chains.
... |
| Method of saying alastin digestion product and assay kit, method of detecting aortic dissection and detection kit | 20060160163 | 20060720 |
| An immunoassay method for conveniently and accurately measuring amount of the elastin degradation product in a circulating fluid of a subject, which is useful for detection of aortic dissection, the method comprising immunologically binding a first antibody and a second antibody to the elastin degradation product, wherein the first antibody and the second antibody are each an antibody selected from the group consisting of a monoclonal antibody produced by a hybridoma HASG-30 (FERM BP-08489), hybridoma HASG-2 (FERM BP-08488) and hybridoma HASG-61-1 (FERM BP-08490) and antibodies having specificity and affinity to a human aortic pelastin degradation product comparable to those of any of the foregoing monoclonal antibodies.
... |
| Elastomeric polymer filament cosmetic implant | 20060136070 | 20060622 |
| A cosmetic implant comprises a filament made from a biocompatible elastomer. The elastomeric filament can be injected or pulled under one or more wrinkles. Once implanted under the wrinkle(s), the filament lifts and supports the tissue above it. Such lifting lessens (and possibly removes altogether) the appearance of the wrinkle(s). The biocompatible elastomeric filament is preferably made from a polyolefinic copolymer material having a triblock polymer backbone comprising polystyrene-polyisobutylene-polystyrene, which is herein referred to as “SIBS”; or alternatively can be made from silicon rubber, expanded polytetrafluorethelyene (ePTFE), polyurethane, polyolefin, copolymers of nylon, copolymers of polyester, or elastin.
... |
| Compositions comprising azelastine and methods of use thereof | 20060110331 | 20060525 |
| The present invention provides pharmaceutical compositions comprising azelastine, or a pharmaceutically acceptable salt or ester thereof including azelastine hydrochloride, and optionally one or more additional active agents. Preferred such compositions further comprise one or more pharmaceutically acceptable carriers or excipients that reduce the amount of post-nasal drip, and/or that minimize or mask the unpleasant bitter taste associated with post-nasal drip, of the compositions into the oral cavity, upon intranasal or ocular administration of the compositions. Especially effective excipients used in the compositions of the present invention are hypromellose as a viscosity modifier and sucralose as a taste-masking agent. The invention also provides methods of treating or preventing certain disorders, or symptomatic relief therefrom, by administering the compositions of the invention to a patient, e.g., for the... |
| Covalently attached collagen vi for cell attachment and proliferation | 20060105455 | 20060518 |
| Surfaces useful for cell culture comprise a support to which is bound a CAR material, and, bound to the CAR material, collagen VI or a biologically active fragment or variant thereof and, optionally, one or more other ECM proteins (or fragments or variants thereof) such as elastin, fibronectin, vitronectin, tenascin, laminin, entactin, aggrecan, decorin, collagen I, collagen III, and collagen IV. Also, optionally present on the surface is one or more polycationic polymers, such as poly-D-lysine or poly-D-ornithine. This surface is used in cell culture to promote cell attachment, survival, and/or proliferation of a number of different cell types such as (a) liver cells (e.g., HepG2 tumor cells, and a newly discovered line of rat liver epithelial stem cells) (b) osteoblasts, such as the murine cell... |
| Elastin prevents occlusion of body vessels by vascular smooth muscle cells | 20060079439 | 20060413 |
| The present invention provides methods and compositions for promoting elastin signaling in smooth muscle cells including vascular smooth muscle cell. The present invention further provides methods of identifying additional agents that promote elasfin signaling.
... |
| Method and composition for restoration of age related tissue loss in the face or selected areas of the body | 20060073178 | 20060406 |
| A treatment method for restoring of age related tissue loss in the face or selected areas of the body is disclosed which includes injecting an injectable composition containing a growth factor and hyaluronic acid as a carrier into the dermis, the hypodermis, or both, in various areas of the face, or selected areas of the body of a person to stimulate collagen, elastin, or fat cell production, thereby restoring age related tissue loss in the face and selected areas of the body. Further disclosed is an injectable composition for restoring of age related tissue loss in the face and selected areas of the body, which contains a growth factor and hyaluronic acid as a carrier for providing time release of the growth factor into tissues. The... |
